Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.58 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.49 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4423000 | 0.92 | PTGDR2 (0.55) | PDE2APTGDR2TP53GAAMAPT | |
| SCHEMBL4424399 | 0.91 | PDE2A (0.60) | PDE2APTGDR2TP53TSHRMAPT | |
| SCHEMBL4414019 | 0.90 | PDE2A (0.57) | PDE2APTGDR2TP53MAPTLMNA | |
| SCHEMBL4412620 | 0.90 | PDE2A (0.60) | PDE2APTGDR2TP53MAPTFYN | |
| SCHEMBL4414065 | 0.88 | PDE2A (0.56) | PDE2APTGDR2TP53TSHRMAPT | |
| SCHEMBL4707864 | 0.88 | PDE2A (0.67) | PDE2APTGDR2TP53GAATSHR | |
| SCHEMBL4412658 | 0.87 | PDE2A (0.72) | PDE2ALMNAFYN | |
| SCHEMBL4602359 | 0.87 | PDE2A (0.58) | PDE2APTGDR2TP53MAPTFYN | |
| SCHEMBL4410796 | 0.84 | PTGDR2 (0.47) | PDE2APTGDR2TP53GAATSHR | |
| SCHEMBL5038881 | 0.84 | PDE2A (0.67) | PDE2APTGDR2TP53GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215752-A1 | Compounds, preparation and therapeutic use thereof | BAY CITY CAPITAL LLC | 2009-08-27 | — | — | US | claimed |
| EP-1910315-A2 | BENZODIAZEPINE DERIVATIVES, THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF | NEURO3D (FR) | 2008-04-16 | — | — | EP | claimed |
| WO-2007026254-A2 | BENZODIAZEPINE DERIVATIVES , THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF | NEURO3D (FR) | 2007-03-08 | — | — | WO | claimed |
| EP-1749824-A1 | Benzodiazepine derivatives, their preparation and the therapeutic use thereof | NEURO3D (FR) | 2007-02-07 | — | — | EP | claimed |
| US-20090215752-A1 | Compounds, preparation and therapeutic use thereof | BAY CITY CAPITAL LLC | 2009-08-27 | — | — | US | disclosed |
| EP-1910315-A2 | BENZODIAZEPINE DERIVATIVES, THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF | NEURO3D (FR) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007026254-A2 | BENZODIAZEPINE DERIVATIVES , THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF | NEURO3D (FR) | 2007-03-08 | — | — | WO | disclosed |
| EP-1749824-A1 | Benzodiazepine derivatives, their preparation and the therapeutic use thereof | NEURO3D (FR) | 2007-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215752-A1 | Compounds, preparation and therapeutic use thereof | PDE12, PDE4B, PDE2A | PDE2A 3/4885PTGDR2 48/4885TP53 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.